EAC 2024 Update in Allergy, Asthma & Immunology

Palm Beach, FL US
May 30, 2024 to June 2, 2024

The 2024 EAC activity will provide conference attendees with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology.  In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases.  By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients.  Topics of discussion will include immunodeficiency, biologics for allergic diseases, allergy immunotherapy, mastocytosis, asthma, atopic dermatitis, HAE, and PIDD.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16.75 contact hours.

Commercial Support
This activity is supported in part by an independent medical education grants from BioCryst .

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:
•    Outline an endotype, phenotype, and updated guideline-based approach to the treatment of asthma 
•    Diagnose and manage hereditary angioedema
•    Discuss current allergy immunotherapy treatment outcomes, guidelines and regulations for respiratory allergies
•    Outline an approach to the use of biologics for allergic diseases, including asthma, CRSwNP, atopic dermatitis and food allergy
•    Evaluate for potential immunodeficiency
•    Diagnose and manage patients with mast cell disorders
•    Develop a management plan for beta-lactam and other drug hypersensitivities
•    Incorporate shared-decision-making into clinical practice
•    Discuss therapeutic options for rescue therapy in patients with asthma
•    Select appropriate patients with atopic dermatitis for patch testing

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 16.75 AMA PRA Category 1 Credit™
  • 16.75 Attendance
  • 16.75 CBRN
Course opens: 
Course expires: 
Event starts: 
05/30/2024 - 2:30pm CDT
Event ends: 
06/02/2024 - 9:30am CDT

EAC 2024 Update in Allergy, Asthma & Immunology
May 30 - June 2, 2024

The Breakers, Palm Beach FL

Thursday, May 30
3:30 – 4:00    Update on beta-lactam allergy, Kimberly Blumenthal, MD
4:00 – 4:30    Testing and management of inducible urticarias, Eric Oliver, MD
4:30 – 5:00    Military accession, retention, and deployment: Defining the role of the allergy consultant, Karla Adams, MD  
5:00 – 5:15    Panel Discussion: Q & A
5:15 – 5:45    The use of biologics in food allergy management, Marcus Shaker, MD    
5:45 – 6:15    Epinephrine: Alternate routes of administration, Michael Blaiss, MD
6:15 – 6:30    Panel Discussion: Q & A

Friday, May 31, 2024
7:45 – 8:15    CVID: Diagnosis and treatment update, Jennifer Heimall, MD
8:15 – 8:45    Mast cell disorders, HaT, POTS and EDS: Sorting fact from fiction, Jonathan Lyons, MD 
8:45 – 8:55    Panel Discussion: Q & A
8:55 – 10:00    PBL: A 43-year-old woman with nasal congestion and wheezing, Ray Davis, MD, Don Bukstein, MD, Kevin Murphy, MD, 
Russell Settipane, MD, Dana Wallace, MD
10:00 – 10:45    Coffee Break: Visits exhibits and posters
10:45 – 11:15    How T2-related comorbidities affect management strategies for severe asthma, Rohit Katial, MD
11:15 – 11:45    AERD: Weighing the risks/benefits of ASA desensitization vs. FESS vs. biologic, Dana Wallace, MD
11:45 – 12:15    Is it achievable to go from control to super responder to remission in asthma?, Michael Blaiss, MD
12:15 – 12:25    Panel Discussion: Q & A
1:20 – 1:50    Operationalizing shared decision making in clinical practice: How I do it, Marcus Shaker, MD
1:50 – 2:20    Angioedema without urticaria: Diagnosis, management and how to document, Aleena Banerji, MD   
2:20 – 2:50    Drug hypersensitivity: Making practical use of practice parameters, Kimberly Blumenthal, MD
2:50 – 3:00    Panel Discussion: Q & A

Saturday, June 1, 2024
7:45 – 8:15    Diagnostic testing approaches for evaluating mastocytosis, Jonathan Lyons, MD
8:15 – 8:45    Atopic dermatitis: Best of guidelines and yardsticks, Mark Boguniewicz, MD
8:45 – 8:55    Panel Discussion: Q & A
8:55 – 10:00    PBL: A 18-year-old woman with occasional asthma exacerbations, Ray Davis, MD, Don Bukstein, MD, Leonard Bacharier, MD, Russell  Settipane, MD, Dana Wallace, MD
10:00 – 10:45    Coffee Break: Visit exhibits and posters
10:45 – 11:45    Debate: ICS/SABA rescue for all vs. just for select asthma patients, Leonard Bacharier, MD vs. Dana Wallace, MD
11:45 – 12:15    Assessing asthma control: How best to do it, Kevin Murphy, MD
12:15 – 12:25    Panel Discussion: Q & A
1:20 – 1:50    Novel perspectives to optimize practice management, Priya Bansal, MD
1:50 – 2:00    Panel Discussion: Q & A
2:00 – 3:00    Debate: Patch testing is underutilized in atopic dermatitis, Mark Boguniewicz, MD vs. Luz Fonacier, MD

Sunday, June 2, 2024
8:15 – 8:45    AIT: How to stay current with USP 797 and practice guidelines, Maureen Peterson, MD 
8:45 – 9:15    The changing economics of AIT, J. Allen Meadows, MD 
9:15 – 9:45    Assessing AIT outcomes: How and why?, Maureen Peterson, MD 
9:45 – 10:15    Remote asthma monitoring: How and why?, Priya Bansal, MD
10:15 – 10:30    Panel Discussion: Q & A

The Breakers
1 South County Road
Palm Beach, FL 33480
United States

All identified relevant financial relationships with ineligible companies have been mitigated. 

Leonard Bacharier, MD – Speaker
Speaker: Sanofi and Regeneron
Advisor: Sanofi and Regeneron, AstraZeneca, DBV Technologies, OM Pharma, Vertex, Aravax 
Researcher: AstraZeneca, OM Pharma

Aleena Banerji, MD – Speaker
Researcher: Ionis, Takeda, Kalvista, Astria
Consultant: Ionis, Takeda, Kalvista, Astria, BioCryst, Intellia, CSL Behring, ADARx, Pharvaris 

Priya Bansal, MD – Speaker
Advisor: AstraZeneca, GSK, Takeda, CSL Behring, Teva, Kalvista
Speaker: AstraZeneca, GSK, Sanofi/Regeneron, Takeda, CSL Behring, Teva    
Consultant: AstraZeneca, GSK, Sanofi/Regeneron, Blueair

Michael Blaiss, MD – Speaker
Advisor: Sanofi, Regeneron
Speaker: Sanofi, Regeneron 
Consultant: Sanofi, Regeneron, GSK, Bryn, ALK, Prollergy, Nectar, Lanier Therapeutics 

Kimberly Blumenthal, MD – Speaker
Researcher: Thermo Fisher
Royalties: UpToDate
Consultant: Denali, Publix Super Market

Mark Boguniewicz, MD – Speaker
Advisor: Regeneron, Sanofi, AbbVie, Amgen, Dermavant, Eli Lilly, Incyte, Janssen, Leo Pharma, Pfizer
Researcher: Regeneron, Sanofi

Don Bukstein, MD – PBL Facilitator
Speaker: Sanofi and Regeneron

Ray Davis, MD – PBL Facilitator 
Consultant: Regeneron, Sanofi, Grifols, Kalvista, AstraZeneca

Luz Fonacier, MD – Speaker
Researcher: Regeneron, Pfizer, AstraZeneca
Consultant: Regeneron, Pfizer, AbbVie, Lilly, Leo Pharma, Dermavant

William Greisner, III, MD – Planner/Moderator/Reviewer
Researcher – Allergy Therapeutics, Allakos, AstraZeneca, GSK

Jennifer Heimall, MD – Speaker
Advisor: CSL Behring, Sumitomo
Speaker: CSL Behring
Researcher: CSL Behring, ADMA, Regeneron, Sumitomo
Royalties: UpToDate
DSMB: Jasper Therapeutics

Rohit Katial, MD – Speaker     
Speaker: AstraZeneca, Pharming
Advisor: AstraZeneca, Sanofi/Regeneron, GSK
Researcher: Sanofi/Regeneron

Jonathan Lyons, MD – Speaker       
Consultant: HI-Bio

J. Allen Meadows, MD – Speaker     
Speaker: Regeneron, Sanofi, Pfizer, Amgen
Consultant: Bryn, Takeda
Advisor: Merck

Kevin Murphy, MD – Speaker
Advisor: AstraZeneca, Sanofi/Regeneron, Pharming
Speaker AstraZeneca, Sanofi/Regeneron, GSK
Consultant: AstraZeneca, Sanofi/Regeneron

Eric Oliver, MD – Speaker
Advisor: Novartis
Researcher: Novartis, Escient

Robert Settipane, MD – Planner/Moderator
Independent Contractor: Regeneron

Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer
Advisor: AbbVie, AstraZeneca, BioCryst, DBV, GSK, Pfizer, Kalvista, Pharming
Speaker: AbbVie, Amgen, AstraZeneca, BioCryst, Genentech, GSK, Regeneron, Sanofi, Takeda, Grifols, Pharming
Independent Contractor: AstraZeneca, BioCryst, DBV, Genentech, GSK, Regeneron, Takeda

Dana Wallace, MD – Speaker/Facilitator
Advisor: AbbVie, Bryn, Genentech, ARS

The following have no relevant financial relationships with ineligible companies to disclose:

Karla Adams, MD – Speaker
Joseph Bellanti, MD – Planner/Speaker 
William Corrao, MD – Planner, Moderator
Ginny Loiselle – Coordinator
Katelyn Loiselle, BSN, RN – Planner 
Maureen Petersen, MD – Speaker
Marcus Shaker, MD - Speaker
Kelli Wilson – Planner

Available Credit

  • 16.75 AMA PRA Category 1 Credit™
  • 16.75 Attendance
  • 16.75 CBRN
Please login or create an account to take this course.